Andrew Guggenhime - Feb 27, 2025 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
PRESIDENT AND CFO
Signature
Andrew Guggenhime, by /s/ Peter N. Efremenko, Attorney-In-Fact
Stock symbol
PCVX
Transactions as of
Feb 27, 2025
Transactions value $
-$367,364
Form type
4
Date filed
3/3/2025, 09:32 PM
Previous filing
Feb 21, 2025
Next filing
Apr 9, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Award $0 +22.8K +20.79% $0.00 132K Feb 27, 2025 Direct F1
transaction PCVX Common Stock Tax liability -$92.7K -1.27K -0.96% $73.02 131K Feb 28, 2025 Direct F2
transaction PCVX Common Stock Tax liability -$275K -3.81K -2.91% $72.10 127K Mar 3, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Award $0 +76K $0.00 76K Feb 27, 2025 Common Stock 76K $74.22 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 7, 2025 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2 Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F3 1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.